Reversion of multidrug resistance in a chemoresistant human breast cancer cell line by β-elemene

Pharmacology

Volumn 89, Issue 5-6, 2012, Pages 303-312

  Xu, Hong Bin ^a   Li, Ling ^a   Fu, Jun ^a   Mao, Xia Ping ^a   Xu, Lu Zhong ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Elemene; MCF 7 cell line; Multidrug resistance

Indexed keywords

BETA ELEMENE; DOXORUBICIN; GLYCOPROTEIN P; RHODAMINE 123;

ARTICLE; BREAST CANCER; CANCER CELL; CYTOTOXICITY; DRUG POTENCY; HUMAN; HUMAN CELL; IC 50; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; SESQUITERPENES; VERAPAMIL;

EID: 84860850339     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000337178     Document Type: Article

References (52)

1. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 335-427.
2. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenbrug RC, Ruevekamp-Helmers MC, Floot BG, Schellens JH: Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999; 59: 4559-4563.
3. Krishna R, Mayer LD: Multidrug resistance (MDR) in cancer: mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000; 11: 265-283.
4. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G: Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 1997; 40(suppl):13-19.
5. Choudhuri S, Klaassen CD: Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 2006; 25: 231-259.
6. Izquierdo MA, Scheffer GL, Flens MJ: Major vault protein LRP-related multidrug resistance. Eur J Cancer 1996; 32: 979-984.
7. Liu YH, Di YM, Zhou ZW, Mo SL, Zhou SF: Multidrug resistance associated proteins and implications in drug development. Clin Exp Pharmacol Physiol 2010; 37: 115-120.
8. Zhou Y, Hopper-Borge E, Shen T, Huang XC, Shi Z, Kuang YH, Furukawa T, Akiyama S, Peng XX, Ashby CR Jr, Chen X, Kruh GD, Chen ZS: Cepharanthine is a potent reversal agent for MRP7 (ABCC10)-mediated multidrug resistance. Biochem Pharmacol 2009; 77: 993-1001.
9. Theis JG, Chan HS, Greenberg ML, Malkin D, Karaskov V, Moncica I, Koren G, Doyle J: Assessment of systemic toxicity in children receiving chemotherapy with cyclosporine for sarcoma. Med Pediatr Oncol 2000; 34: 242-249.
10. Shen F, Bailey BJ, Chu S, Bence AK, Xue XJ, Erickson P, Safa AR, Beck WT, Erickson LC: Dynamic assessment of mitoxantrone resistance and modulation of multidrug resistance by valspodar (PSC833) in multidrug resistance human cancer cells. J Pharmacol Exp Ther 2009; 330: 423-429.
11. Qi J, Wang SB, Liu GY, Peng H, Wang JH, Zhu ZP, Yang CZ: Pyronaridine, a novel modulator of P-glycoprotein-mediated multidrug resistance in tumor cells in vitro and in vivo. Biochem Biophys Res Commun 2004; 319: 1124-1131.
12. Werle M: Natural and synthetic polymers as inhibitors of drug efflux pumps. Pharm Res 2008; 25: 500-511.
13. Barthomeuf C, Grassi J, Demeule M, Fournier C, Boivin D, Béliveau R: Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cni diadin. Cancer Chemother Pharmacol 2005; 56: 173-181.
14. Huang M, Jin J, Sun H, Liu GT: Reversal of P-glycoprotein-mediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus Schizandrae. Cancer Chemother Pharmacol 2008; 62: 1015-1026.
15. Tang XH, Qin SK, Xie T: Status and progress of basic researches of elemene injection for anti-tumor. Chin Clin Oncol 2010; 15: 266-273.
16. Hu J, Jin W, Yan PM: Reversal of resistance to adriamycin in human breast cancer cell line MCF-7/ADM by -elemene (in Chinese). Zhonghua Zhong Liu Za Zhi 2004; 26: 268-270.
17. Hansen MB, Nielsen SE, Berg K: Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 1989; 119: 203-210.
18. Qi J, Yang CZ, Wang CY, Wang SB, Yang M, Wang JH: Function and mechanism of pyronaridine: a new inhibitor of P-glycoproteinmediated multidrug resistance. Acta Pharmacol Sin 2002; 23: 544-550.
19. Ji BS, He L, Liu GQ: Modulation of P-glycoprotein function by amlodipine derivatives in brain microvessel endothelial cells of rats. Acta Pharmacol Sin 2005; 26: 166-170.
20. Gong J, Traganos F, Darzynkiewicz Z: A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal Biochem 1994; 218: 314-319.
21. Pearce HL, Safa AR, Bach NJ, Winter MA, Cirtain MC, Beck WT: Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc Natl Acad Sci USA 1989; 86: 5128-5132.
22. Tietze F: Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 1969; 27: 502-522.
23. Habig WH, Pabst MJ, Jakoby WB: Glutathione S-transferases: the first enzymatic step in mercapturic acid formation. J Biol Chem 1974; 249: 7130-7139.
24. Zaman GJ, Lankelma J, van Tellingen O, Beijen J, Dekker H, Paulusma C, Oude Elferink RP, Baas F, Borst P: Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc Natl Acad Sci USA 1995; 92: 7690-7694.
25. Lutzky J, Astor MB, Taub RN, Baker MA, Bhalak K, Gervasoni JE, Rosado M, Srevart V, Kirshna S, Hindenburg AA: Role of glutathione and dependent enzymes in anthracycline-resistant HL60/AR cells. Cancer Res 1989; 49: 4120-4125.
26. Fojo T, Bates S: Strategies for reversing drug resistance. Oncogene 2003; 22: 7512-7523.
27. Kars MD, Iseri OD, Gunduz U, Molnar J: Reversal of multidrug resistance by synthetic and natural compounds in drug-resistant MCF-7 cell lines. Chemotherapy 2008; 54: 194-200.
28. Jones KH, Liu JJ, Rochm JS, Eckel JJ, Eckel TT, Stickrath CR, Triola CA, Jiang Z, Bartoli GB, Cornwell DG: Gamma-tocopheryl quinone stimulates apoptosis in drug sensitive and multidrug-resistant cancer cells. Lipids 2002; 37: 173-184.
29. Li D, Jang SH, Kim J, Wientjes MG, Au JL: Enhanced drug induced apoptosis associated with P-glycoprotein overexpression is specific to antimicrotubule agents. Pharm Res 2003; 20: 45-50.
30. Weisburg JH, Curcio M, Caron PC, Raghu G, Mechetner EB, Roepe PD, Scheinberg DA: The multidrug resistance phenotype confers immunological resistance. J Exp Med 1996; 183: 2699-2704.
31. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995; 270: 1326-1331.
32. Bezombes C, Maestre N, Laurent G, Levade T, Bettaieb A, Jaffrezou JP: Restoration of TNF-alpha-induced ceramide generation and apoptosis in resistant human leukemia KG1a cells by the P-glycoprotein blocker PSC833. FASEB J 1998; 12: 101-109.
33. Tishler RB, Lamppu DM, Park S, Price BD: Microtubule-active drugs taxol, vinblastine, and nocodazole increase the levels of transcriptionally active p53. Cancer Res 1995; 55: 6021-6025.
34. Wang LG, Liu XM, Kreis W: The effect of tubulin binding agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 1999; 44: 355-361.
35. Sorenson CM, Eastman A: Mechanism of cis-diamminedichloroplatinum(II)- induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res 1988; 48: 4484-4488.
36. Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW: The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspasedependent apoptosis. Proc Natl Acad Sci USA 1998; 95: 7024-7029.
37. Ruefli AA, Tainton KM, Darcy PK, Smyth MJ, Johnstone RW: P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death Differ 2002; 9: 1266-1272.
38. Belhoussine R, Morjani H, Sharonov S, Ploton D, Manfait M: Characterization of intracellular pH gradients in human multidrugresistant tumor cells by means of scanning microspectrofluorometry and dual-emission-ratio probes. Int J Cancer 1999; 81: 81-89.
39. Gottlieb RA, Nordberg J, Skowronski E, BabiorBM: Apoptosis induced Jurkat cells by several agents is preceded by intracellular acidification. Proc Natl Acad Sci USA 1996; 93: 654-658.
40. Loe DW, Almquist KC, Deeley RG, Cloe SP: Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles: Demonstration of glutathione-dependent vincristine transport. J Biol Chem 1996; 271: 9675-9682.
41. Rappa G, Lorico A, Flavell RA, Sartorelli AC: Evidence that the multidrug Resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins. Cancer Res 1997; 57: 5232-5237.
42. Renes J, Vries de EG, Nienhuis EF, Jansen PL, Muller M: ATP-and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br J Pharmacol 1999; 126: 681-688.
43. Salerno M, Garnier-Suillerot A: Kinetics of glutathione and daunorubicin efflux from multidrug resistance protein overexpressing small-cell lung cancer cells. Eur J Pharmacol2001; 421: 1-9.
44. Evers R, Kool M, Smith AJ, van Deemter L, de Haas M, Borst P: Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1-and MRP2-mediated transport. Br J Cancer 2000; 83: 366-374.
45. Rebbeor JF, Connolly GC, Ballatori N: Inhibition of Mrp2-and Ycf1p-mediated transport by reducing agents: evidence for GSH transport on rat Mrp2. Biochim Biophys Acta 2000; 1559: 171-178.
46. Loe DW, Oleschuk CJ, Deeley RG, Cloe SP: Structure-activity studies of verapamil analogs that modulate transport of leukotriene C 4 and reduced glutathione by multidrug resistance protein MRP1. Biochem Biophys Res Commun 2000; 275: 795-803.
47. Mao Q, Deeley RG, Cole SP: Functional reconstitution of substrate transport by purified multidrug resistance protein MRP1 (ABCC1) in phospholipid. J Biol Chem 2000; 275: 34166-34172.
48. Loe DW, Deeley RG, Cole SP: Biology of the multidrug resistance- associated protein MRP. Eur J Cancer 1996; 32: 945-947.
49. Trompier D, Chang XB, Barattin R, et al: Verapamil and its derivative trigger apoptosis through glutathione extrusion by multidrug resistance protein MRP1. Cancer Res 2004; 64: 4950-4956.
50. Muñoz-Martínez F, Lu P, Cortés-Selva F, et al: Celastraceae sesquiterpenes as a new class of modulators that bind specifically to human P-glycoprotein and reverse cellular multidrug resistance. Cancer Res 2004; 64: 7130-7138.
51. Hu YP, Lin J, Wang QD, et al: Reversal of adriamycin resistance by verapamil and ligustrazini in mouse Ehrlich ascites cancer (in Chinese). Yao Xue Xue Bao 1993; 28: 75-78.
52. Fairchild CR, Ivy SP, Kao-Shan CS, et al: Isolation of amplified and overexpressed DNAsequences from adriamycin-resistant human breast cancer cells. Cancer Res 1987; 47: 5141-5148.